Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea.
Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea.
J Vasc Interv Radiol. 2020 Apr;31(4):544-550. doi: 10.1016/j.jvir.2019.04.006. Epub 2019 Jun 22.
To evaluate the efficacy and safety of ultrasound (US)-guided radiofrequency (RF) ablation in the treatment of facial microcystic lymphatic malformations (mLMs) or mixed venolymphatic malformations (VLMs) and to introduce the "induced-paralysis" technique with the use of an injectable electrode to minimize neural complications.
Data from patients with symptomatic facial mLMs or mixed VLMs who underwent US-guided RF ablation in 2014-2017 were retrospectively reviewed. Computed tomography (CT) and/or magnetic resonance (MR) imaging was used to localize any functional structures close to the target lesion. Treatment outcome was assessed by 4-point cosmetic grading score (CGS). Treatment outcome was compared between patients with vs without a functional structure close to the lesion and those treated with a noninjectable vs an injectable electrode. Immediate and late complications were assessed during follow-up.
Data from 15 patients were evaluated. Initial CGS and median volume were significantly decreased at the last follow-up in all patients (from 4 to 1 and from 7 mL to 0.7 mL, respectively; P < .05). Treatment outcome differed significantly between those with and without a functional structure on CT or MR imaging (P < .05) but showed no difference between noninjectable (n = 9) and injectable electrodes (n = 6). Two cases of transient cranial nerve palsy were seen in the noninjectable electrode group.
US-guided RF ablation is effective in patients with facial mLMs or mixed VLMs. The induced-paralysis technique with an injectable electrode has the potential to ensure technical safety without compromising efficacy.
评估超声引导下射频(RF)消融治疗面部微囊性淋巴管畸形(mLMs)或混合静脉淋巴管畸形(VLMs)的疗效和安全性,并介绍使用可注射电极的“诱导瘫痪”技术,以最大限度地减少神经并发症。
回顾性分析 2014 年至 2017 年期间接受超声引导下 RF 消融治疗的有症状面部 mLMs 或混合 VLMs 患者的数据。使用计算机断层扫描(CT)和/或磁共振成像(MR)定位靠近靶病变的任何功能结构。采用 4 分美容分级评分(CGS)评估治疗效果。比较了病变附近有/无功能结构的患者和使用非注射电极与可注射电极治疗的患者之间的治疗效果。在随访期间评估即刻和迟发性并发症。
共评估了 15 例患者的数据。所有患者的初始 CGS 和中位数体积在最后一次随访时均显著降低(分别从 4 分降至 1 分,从 7 毫升降至 0.7 毫升;P<0.05)。CT 或 MR 成像上有/无功能结构的患者之间的治疗效果差异有统计学意义(P<0.05),但非注射电极(n=9)和可注射电极(n=6)之间无差异。非注射电极组有 2 例出现短暂性颅神经麻痹。
超声引导下 RF 消融治疗面部 mLMs 或混合 VLMs 有效。使用可注射电极的“诱导瘫痪”技术具有确保技术安全性而不影响疗效的潜力。